Publication: A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: is existing evidence good enough to support policy decision-making?
2
0
Issued Date
2021
Resource Type
Language
eng
File Type
application/pdf
ISSN
14737167
Other identifier(s)
2-s2.0-85111630764
Rights Holder(s)
Scopus
Bibliographic Citation
Expert Review of Pharmacoeconomics and Outcomes Research. Vol 21, No.6 (2021), p.1159-1178
Suggested Citation
Nagi M.A., Luangsinsiri C., Thavorncharoensap M. A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: is existing evidence good enough to support policy decision-making?. Expert Review of Pharmacoeconomics and Outcomes Research. Vol 21, No.6 (2021), p.1159-1178. doi:10.1080/14737167.2021.1954508 Retrieved from: https://hdl.handle.net/20.500.14740/8006
Author(s)
Abstract
Introduction: A vaccine introduction process should be systematic and transparent and take into account many factors, including cost-effectiveness evidence. This study aimed to assess quantity, characteristic, and quality of economic evaluation (EE) studies on vaccines performed in Middle East and North Africa (MENA) countries. Areas covered: PubMed and Scopus electronic databases were searched since inception to December 2019 to identify published EE studies of vaccines, which were conducted in the 26 MENA countries. Methodological quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Expert opinion: Of the 616 studies identified, 46 were included in the review. Most studies (65%) were conducted in Iran, Israel, and Turkey. The most commonly evaluated vaccines were rotavirus vaccine (n = 15; 33%), human Papillomavirus vaccine (n = 8; 17%), and pneumococcal vaccine (n = 7; 15%). We classified 5 (11%), 27 (59%), 12 (26%), and 2 (4%) studies as excellent, good, moderate, and poor quality, respectively. There were limited cost-effectiveness evidences in the region. It is imperative to have local guidelines on good practice and reporting, availability of local data, and funding sources to improve quantity and quality of EE studies of vaccines in the region, thereby, facilitating transparent and consistent decision-making processes. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Subject(s)
Pneumococcus vaccine
Rotavirus vaccine
Vaccine
Wart virus vaccine
Africa
Clinical decision making
Cost effectiveness analysis
Disability-adjusted life year
Economic aspect
Health care policy
Health care system
Human
Quality adjusted life year
Review
Risk factor
Systematic review
Cost benefit analysis
Economics
Management
Middle East
Africa, Northern
Cost-Benefit Analysis
Humans
Middle East
Policy Making
Vaccines
Rotavirus vaccine
Vaccine
Wart virus vaccine
Africa
Clinical decision making
Cost effectiveness analysis
Disability-adjusted life year
Economic aspect
Health care policy
Health care system
Human
Quality adjusted life year
Review
Risk factor
Systematic review
Cost benefit analysis
Economics
Management
Middle East
Africa, Northern
Cost-Benefit Analysis
Humans
Middle East
Policy Making
Vaccines